The Pre-Seed Biotech Website: Minimum Viable Credibility for Your First Raise

A pre-seed biotech company is a strange thing to put on the internet. You are asking for capital based on a hypothesis and a set of credentials, not a product. There is no revenue to show, often no data beyond preliminary results, and the technology that matters most is the part you cannot fully disclose. And yet the website is one of the first things a prospective investor does after your intro call. They will open it in a browser tab while you are still talking. What they see in the next ten seconds either reinforces the impression you just made or quietly undercuts it.

The mistake most first-time founders make is treating the pre-seed site as either unnecessary or as a miniature version of a Series B site. Both are wrong. The site is necessary, because its absence reads as a lack of seriousness in a field where diligence starts with a search. But it should not pretend to be something it is not. A pre-seed company that presents a sprawling pipeline table with five programs, none of which have entered the clinic, looks less credible than one that shows a single clear thesis executed well. Overreach is more damaging than modesty at this stage.

What you are actually building is minimum viable credibility. Enough substance to demonstrate that the science is real and the team can execute, without manufacturing a track record you do not have. Three things carry that weight.

The core narrative comes first

Before design, before a logo, the site needs one thing settled: a clear statement of what the company does, why it matters, and why this team is the one to do it. This is harder than it sounds, because the version in your head is usually either too technical to land with a generalist partner or too vague to survive a scientist reading it. The pre-seed site has to thread that needle in a single home page.

The strongest structure is simple. Lead with the problem in terms a domain-literate reader recognizes as real and unsolved. State your approach in one or two sentences that name the actual mechanism, not a category. "A small-molecule inhibitor of a previously undruggable target" says something. "A next-generation therapeutic platform" says nothing, and a scientist reads the emptiness immediately. Then establish why you can do this: the specific expertise, the prior work, the insight that competitors have missed. A pre-seed raise is largely a bet on the founders, so the narrative has to make the founders legible.

Protecting IP is a design constraint, not an afterthought

Every pre-seed founder feels the tension between showing enough to be compelling and disclosing enough to be dangerous. Your core technology may be the subject of a provisional patent, or unfiled and protected only as a trade secret. What goes on a public website can affect both. Public disclosure can start clocks and, in some cases, compromise patentability in jurisdictions without a grace period.

The practical rule is that the website should communicate the value of the science without teaching a competent reader how to reproduce it. You describe the target and the therapeutic rationale, not the specific chemical series. You describe the diagnostic capability, not the assay chemistry that makes it work. This is not evasive. Done well, it reads as disciplined, and disciplined is exactly the impression you want a sophisticated investor to form. If protecting the crown jewels requires coordination with your patent counsel about what is already disclosed and what remains confidential, that coordination is part of building the site properly. This is one place where a builder who understands both the science and the stakes saves you from an expensive mistake.

Looking professional without overpromising

The third job is the one founders underestimate: the site simply has to look like it was made by people who take themselves seriously. A template with a stock image of a gloved hand holding a pipette, generic copy about "revolutionizing healthcare," and a contact form that goes nowhere does active harm. It signals that you spent no real thought on how you present, which a careful investor extends to a worry about how you will execute.

Professional does not mean expensive or elaborate. At the pre-seed stage it means a clean, custom, fast-loading site with copy that is precise and free of filler, a design that does not fight the content, and technical execution that works on the phone an associate pulls out in a hallway. One to three pages is enough. What matters is that every element is deliberate and nothing overpromises. A pre-seed site that quietly does its job well outperforms a bloated one that strains to look like a company three rounds ahead of where you are.

This is the thinking behind the Launch tier: a focused site built to establish credibility for a first raise, priced and scoped for where a newly incorporated company actually is. Not a placeholder, and not a Series A build you do not need yet. The right amount of site for the check you are trying to close.

The pre-seed website is not where you win the round. You win the round in conversations, on the strength of the science and the team. But the site is where a good conversation goes to get confirmed or quietly doubted. Build it so that when the investor opens that tab, everything they see makes the case you just made in person a little more believable.